Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na+/I- Symporter.

Endocrinology | 2019

The Na+/iodide (I-) symporter (NIS), a glycoprotein expressed at the basolateral plasma membrane of thyroid follicular cells, mediates I- accumulation for thyroid hormonogenesis and radioiodide therapy for differentiated thyroid carcinoma. However, differentiated thyroid tumors often exhibit lower I- transport than normal thyroid tissue (or even undetectable I- transport). Paradoxically, the majority of differentiated thyroid cancers show intracellular NIS expression, suggesting abnormal targeting to the plasma membrane. Therefore, a thorough understanding of the mechanisms that regulate NIS plasma membrane transport would have multiple implications for radioiodide therapy. In this study, we show that the intracellularly facing carboxy-terminus of NIS is required for the transport of the protein to the plasma membrane. Moreover, the carboxy-terminus contains dominant basolateral information. Using internal deletions and site-directed mutagenesis at the carboxy-terminus, we identified a highly conserved monoleucine-based sorting motif that determines NIS basolateral expression. Furthermore, in clathrin adaptor protein (AP)-1B-deficient cells, NIS sorting to the basolateral plasma membrane is compromised, causing the protein to also be expressed at the apical plasma membrane. Computer simulations suggest that the AP-1B subunit σ1 recognizes the monoleucine-based sorting motif in NIS carboxy-terminus. Although the mechanisms by which NIS is intracellularly retained in thyroid cancer remain elusive, our findings may open up avenues for identifying molecular targets that can be used to treat radioiodide-refractory thyroid tumors that express NIS intracellularly.

Pubmed ID: 30496374 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


KDEL ER Marker (10C3) (antibody)

RRID:AB_784161

This monoclonal targets KDEL ER Marker (10C3)

View all literature mentions

beta-Catenin (6B3) Rabbit mAb (antibody)

RRID:AB_823447

This monoclonal targets beta-Catenin

View all literature mentions

E-Cadherin (24E10) Rabbit mAb (antibody)

RRID:AB_2291471

This monoclonal targets E-Cadherin (24E10) Rabbit mAb

View all literature mentions

HA-Tag (C29F4) Rabbit mAb (antibody)

RRID:AB_1549585

This monoclonal targets HA-Tag

View all literature mentions

KDEL ER Marker (10C3) (antibody)

RRID:AB_784161

This monoclonal targets KDEL ER Marker (10C3)

View all literature mentions

beta-Catenin (6B3) Rabbit mAb (antibody)

RRID:AB_823447

This monoclonal targets beta-Catenin

View all literature mentions

E-Cadherin (24E10) Rabbit mAb (antibody)

RRID:AB_2291471

This monoclonal targets E-Cadherin (24E10) Rabbit mAb

View all literature mentions

HA-Tag (C29F4) Rabbit mAb (antibody)

RRID:AB_1549585

This monoclonal targets HA-Tag

View all literature mentions